检测亚临床类风湿关节炎相关间质性肺病的风险评分
研究在ESPOIR和TRANSLATE2两个前瞻性类风湿关节炎队列中,对无肺部症状且接受胸部高分辨率CT的患者开发并验证亚临床RA-ILD风险评分;发现MUC5B rs35705950 T等位基因、男性、发病年龄较大和平均DAS28-ESR升高为独立风险因素,风险评分在发现队列和复制队列的AUC分别为0.82和0.78。
要点
- 亚临床RA-ILD在发现队列和复制队列的患病率分别为19.0%和16.9%。
- MUC5B rs35705950 T等位基因、男性、发病年龄较大和平均DAS28-ESR升高为独立风险因素。
- 风险评分在发现队列和复制队列的AUC分别为0.82和0.78。
核心结论
- 研究开发并验证了一个可帮助识别亚临床RA-ILD高风险患者的风险评分。
- 研究结果支持MUC5B rs35705950对亚临床RA-ILD风险的重要贡献。
研究设计与样本
- 研究纳入来自2个前瞻性RA队列(分别为ESPOIR和TRANSLATE2)的无肺部症状且接受胸部HRCT的患者,包括发现人群和复制人群。
- 所有患者均进行MUC5B rs35705950基因分型,在发现人群中通过多元逻辑回归开发基于独立风险因素的风险评分,并在复制人群中进行验证。
主要发现
- 发现人群包括163例RA患者,复制人群包括89例RA患者。
- 亚临床RA-ILD的患病率在发现人群为19.0%,在复制人群为16.9%。
- 在发现人群中,亚临床RA-ILD的独立风险因素包括:MUC5B rs35705950 T等位基因(OR 3.74 [95% CI 1.37, 10.39])、男性(OR 3.93 [95% CI 1.40, 11.39])、发病年龄较大(每岁OR 1.10 [95% CI 1.04, 1.16])和平均DAS28-ESR升高(每单位OR 2.03 [95% CI 1.24, 3.42])。
- 推导的风险评分在发现人群的ROC曲线下面积为0.82(95% CI 0.70-0.94),在复制人群为0.78(95% CI 0.65-0.92)。
- 从模型中排除MUC5B rs35705950后拟合优度较低(似然比检验,P = 0.01)。
关键数值与推荐
- 亚临床RA-ILD的独立风险因素:MUC5B rs35705950 T等位基因(OR 3.74 [95% CI 1.37, 10.39])、男性(OR 3.93 [95% CI 1.40, 11.39])、发病年龄较大(每岁OR 1.10 [95% CI 1.04, 1.16])、平均DAS28-ESR升高(每单位OR 2.03 [95% CI 1.24, 3.42])。
- 风险评分AUC:发现人群0.82(95% CI 0.70-0.94),复制人群0.78(95% CI 0.65-0.92)。
- 排除MUC5B rs35705950后拟合优度较低(似然比检验,P = 0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients at high risk of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) would benefit from being identified before the onset of respiratory symptoms; this can be done by screening patients with the use of chest high-resolution computed tomography (HRCT). Our objective was to develop and validate a risk score for patients who have subclinical RA-ILD. METHODS: Our study included a discovery population and a replication population from 2 prospective RA cohorts (ESPOIR and TRANSLATE2, respectively) without pulmonary symptoms who had received chest HRCT scans. All patients were genotyped for MUC5B rs35705950. After multiple logistic regression, a risk score based on independent risk factors for subclinical RA-ILD was developed in the discovery population and tested for validation in the replication population. RESULTS: The discovery population included 163 patients with RA, and the replication population included 89 patients with RA. The prevalence of subclinical RA-ILD was 19.0% and 16.9%, respectively. In the discovery population, independent risk factors for subclinical RA-ILD were presence of the MUC5B rs35705950 T allele (odds ratio [OR] 3.74 [95% confidence interval (95% CI) 1.37, 10.39]), male sex (OR 3.93 [95% CI 1.40, 11.39]), older age at RA onset (for each year, OR 1.10 [95% CI 1.04, 1.16]), and increased mean Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (for each unit, OR 2.03 [95% CI 1.24, 3.42]). We developed and validated a derived risk score with receiver operating characteristic areas under the curve of 0.82 (95% CI 0.70-0.94) for the discovery population and 0.78 (95% CI 0.65-0.92) for the replication population. Excluding MUC5B rs35705950 from the model provided a lower goodness of fit (likelihood ratio test, P = 0.01). CONCLUSION: We developed and validated a risk score that could help identify patients at high risk of subclinical RA-ILD. Our findings support an important contribution of MUC5B rs35705950 to subclinical RA-ILD risk.
引用
- Juge PA, Granger B, Debray MP, et al. A Risk Score to Detect Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2022. PMID: 35583934. doi:10.1002/art.42162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。